Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1471-230X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Relationship of sarcopenia with steatohepatitis and advanced liver fibrosis in non-alcoholic fatty liver disease: a meta-analysis ; volume:18 ; number:1 ; day:19 ; month:4 ; year:2018 ; pages:1-6 ; date:12.2018
BMC gastroenterology ; 18, Heft 1 (19.4.2018), 1-6, 12.2018
- Urheber
-
Yu, Rui
- Beteiligte Personen und Organisationen
-
Shi, Qiangwei
Liu, Lei
Chen, Lidong
SpringerLink (Online service)
- DOI
-
10.1186/s12876-018-0776-0
- URN
-
urn:nbn:de:101:1-2018062622252604888140
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:33 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yu, Rui
- Shi, Qiangwei
- Liu, Lei
- Chen, Lidong
- SpringerLink (Online service)
Ähnliche Objekte (12)
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
Non-alcoholic fatty liver disease
Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment
Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients
Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
The Differentiation of Intestinal-Failure-Associated Liver Disease from Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
Non-alcoholic fatty liver disease
Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment
Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients
Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
The Differentiation of Intestinal-Failure-Associated Liver Disease from Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis
Addressing the liver progenitor cell response and hepatic oxidative stress in experimental non-alcoholic fatty liver disease/non-alcoholic steatohepatitis using amniotic epithelial cells
Non-alcoholic fatty liver disease (NAFLD)/non-alcoholic steatohepatitis (NASH)-related liver fibrosis : mechanisms, treatment and prevention
Non-alcoholic fatty liver disease
Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease
Beneficial effect of omarigliptin on diabetic patients with non-alcoholic fatty liver disease/non-alcoholic steatohepatitis
Transaminase concentrations cannot separate non-alcoholic fatty liver and non-alcoholic steatohepatitis in morbidly obese patients irrespective of histological algorithm
Metabolic improvement and liver regeneration by inhibiting CXXC5 function for non-alcoholic steatohepatitis treatment
Progression from Non-alcoholic Steatohepatitis to Advanced Liver Diseases and Mortality Among Medicare Patients
Bioprotective Role of Phytocompounds Against the Pathogenesis of Non-alcoholic Fatty Liver Disease to Non-alcoholic Steatohepatitis: Unravelling Underlying Molecular Mechanisms
Bioengineering liver microtissues for modeling non-alcoholic fatty liver disease
The Differentiation of Intestinal-Failure-Associated Liver Disease from Nonalcoholic Fatty Liver and Nonalcoholic Steatohepatitis
Liver ASK1 protects from non‐alcoholic fatty liver disease and fibrosis